Stock weekly review: Biotech stocks Evotec and MorphoSys outperform, but there is no broad market movement

Stock weekly review: Biotech stocks Evotec and MorphoSys outperform, but there is no broad market movement

The stock market week started on Monday with a level of 16,079.86 points and ended with 15,949.84 points. The market was unable to maintain the 16,000 point mark due to a lack of positive company announcements and news in general. Nevertheless, there was a positive overall mood due to good quarterly figures in the previous weeks. There is enough purchasing power in the market and after the budget deficit has been clarified, the new all-time high in the DAX could be tested. However, renewed economic concerns from China could bring disruption to the market. This week the focus was on the analysts, who led to price fireworks for MorphoSys and Evotec. Gold prices remained below the USD 2,000.00 mark and there are analyst opinions in both directions. The weakness of the dollar was reflected in positive gold prices. Many believe that gold will only see a recovery once the yield curve begins to point downward again.

According to a report from www.nebenwerte-magazin.com, it is important to stay vigilant, hedge, weigh risks and set stops. Reference is also made to the “sister site” www.gold-magazin.com, which offers reports on gold, gold mining stocks and everything related to the shiny precious metal.